{"id":"F2020L00307","name":"National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2020 (PB 29 of 2020)","slug":"national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":440416,"registerId":"F2020L00307-fast-fetch-1775956048936","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2020 (PB 29 of 2020)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![Commonwealth Coat of Arms of Australia](image.001.jpeg)\n\n \n\nPB 29 of 2020\n\n \n\nNational Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2020\n\nI, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination under subsection 84AG(1) of the National Health Act 1953.\n\nDated     23   March 2020\n\n \n\n \n\n \n\n \n\nTHEA DANIEL\n\nAssistant Secretary\n\nPricing and PBS Policy Branch\n\nTechnology Assessment and Access Division\n\nDepartment of Health\n\n \n\n \n\n \n\nContents\n\n1  Name\n\n2  Commencement\n\n3  Authority\n\n4  Repeal of previous instrument\n\n5  Definitions\n\n6  Therapeutic Groups\n\n7  Drugs in therapeutic groups\n\nSchedule 1—Therapeutic groups and listed drugs\n\nPart 1—ATRA group\n\n \n\n \n\n1  Name\n\n1.    This instrument is the National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2020.\n2.    This instrument may also be cited as PB 29 of 2020.\n\n\n2  Commencement\n\n (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.\n\n \n\n- Commencement information\n- Column 1 Column 2 Column 3\n- Provisions Commencement Date/Details\n- The whole of this instrument. The date after this instrument is registered.\n\n\nNote: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.\n\n (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.\n\n3  Authority\n\n  This instrument is made under subsection 84AG(1) of the National Health Act 1953.\n\n4  Repeal of previous instrument\n\n  The National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 is repealed.\n\n5  Definitions\n\n  In this Determination:\n\nAct means the National Health Act 1953.\n\nATRA group means the Angiotensin II receptor antagonist group.\n\n6  Therapeutic groups\n\nFor paragraph 84AG(1)(a) of the Act, a therapeutic group is a group mentioned in a Part of Schedule 1.\n\n7  Drugs in therapeutic groups\n\nFor paragraph 84AG(1)(b) of the Act, each listed drug mentioned in a Part of Schedule 1 is in the therapeutic group mentioned in the Part.\n\n\n\n\nSchedule 1—Therapeutic groups and listed drugs\n\nPart 1—ATRA group\n\n| Item | Listed drug |\n| --- | --- |\n| 1 | Eprosartan |\n| 2 | Losartan |\n\n\n \n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"flash_summary":{"complexity_score":2,"scope_assessment":{"changed":false,"description":"The Determination stays within the statutory power in subsection 84AG(1) of the National Health Act 1953 (s 3). It repeals the 2010 Determination (s 4) and confines itself to naming therapeutic groups and listing drugs (ss 6–7; Schedule 1). It does not itself expand the Minister's statutory authority; it changes only the administrative listing (Schedule 1: ATRA group — eprosartan, losartan)."},"complexity_factors":["Narrow subject-matter: only defines therapeutic groups and lists drugs (ss 6–7, Schedule 1).","Short instrument with few provisions — limited cross-references beyond the Act (ss 1–2, 4).","Made under a single statutory hook (subsection 84AG(1)) so legal scope depends on that provision (s 3).","Administrative character: delegate (Assistant Secretary) signs the instrument (instrument header), reducing policy complexity but raising standard delegation/authorization checks.","Repeal of prior instrument (s 4) can affect continuity; complexity arises only if stakeholders need to compare lists between instruments.","Sparse definitions: only items defined are 'Act' and 'ATRA group' (s 5), limiting interpretive ambiguity but requiring reference to the Act for substantive effect."],"plain_english_summary":"This Determination, made by an Assistant Secretary under subsection 84AG(1) of the National Health Act 1953, sets out which medicines belong to named therapeutic groups used in the Pharmaceutical Benefits context. It repeals the 2010 Determination and records that the ATRA (Angiotensin II receptor antagonist) group includes eprosartan and losartan (Schedule 1; ss 3–7). The instrument is procedural: it allocates drugs to groups that the Pharmaceutical Benefits framework will treat as a unit for administrative and pricing purposes."},"kimi_summary":{"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This instrument maintains its original narrow purpose: establishing therapeutic groups for pharmaceutical benefits. The 2020 version appears to be a straightforward re-enactment/replacement of the 2010 version with the same limited scope — establishing the ATRA group for blood pressure medications. There is no evidence of scope creep; it remains focused on its specific technical function under the National Health Act."},"complexity_factors":["Very short instrument (approximately 2 pages of substantive content)","Only 2 defined terms in section 5 ('Act' and 'ATRA group')","Simple structure: definitions, operative provisions, and a single schedule with a table","No nested exceptions or conditional logic","Minimal cross-referencing (only references to the parent Act and its specific subsection)","Single therapeutic group established with only 2 listed drugs","Straightforward repeal and replacement of previous instrument"],"plain_english_summary":"This Determination creates an \"Angiotensin II receptor antagonist\" (ATRA) therapeutic group under the PBS, grouping Eprosartan and Losartan as clinically similar blood‑pressure medicines. It affects patients, prescribers, pharmacists and manufacturers by determining which products compete for PBS subsidy. Grouping aims to lower government and patient costs through price competition and standardised patient co‑payments. This 2020 version replaces the 2010 framework for these drugs."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020","history":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020/history","analysis":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020/analysis","conflicts":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020/conflicts","importantCases":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020/important-cases","documents":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2020-pb-29-of-2020/documents"}}